Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session moderated by Stephen Willey, senior biotech analyst at Stifel.
Seely described Lyell as a cell therapy c
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Lyell Immunopharma reports Q2 2025 with a narrower loss than expected, driven by cost controls. Clinical progress for CAR T-cell therapy LYL314 remains strong, with pivotal trials advancing. Cash runway extends to mid-2027.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities.
Lyell Immunopharma shares fell following the release of initial clinical data from its Phase 1 trial of LYL797, a reprogrammed CAR T-cell product. The company reported some severe cases reported in patients with lung metastases.
U.S. stocks were lower, with the Dow Jones index falling over 250 points on Friday. Shares of Argan, Inc. (NYSE: AGX) rose sharply during Friday’s session as the company reported better-than-expected results for its fourth quarter.
